Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

Michael D Prados; William M Wara; Penny K Sneed; Michael McDermott; Susan M Chang; Jane Rabbitt; Margaretta Page; Mary Malec; Richard L Davis; Philip H Gutin; Kathleen Lamborn; Charles B Wilson; Theodore L Phillips; David A Larson

doi:10.1016/S0360-3016(00)01458-9

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

Michael D Prados, William M Wara, Penny K Sneed, Michael McDermott, Susan M Chang, Jane Rabbitt, Margaretta Page, Mary Malec, Richard L Davis, Philip H Gutin, Kathleen Lamborn, Charles B Wilson, Theodore L Phillips, David A Larson

Miami Neuroscience Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	International Journal of Radiation Oncology Biology Physics
Volume	49
DOIs	https://doi.org/10.1016/S0360-3016(00)01458-9
State	Published - Jan 1 2001

Disciplines

Survival Analysis
Medicine and Health Sciences
Other Medical Specialties

Access to Document

10.1016/S0360-3016(00)01458-9License: Unspecified

Cite this

Prados, M. D., Wara, W. M., Sneed, P. K., McDermott, M., Chang, S. M., Rabbitt, J., Page, M., Malec, M., Davis, R. L., Gutin, P. H., Lamborn, K., Wilson, C. B., Phillips, T. L., & Larson, D. A. (2001). Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics, 49. https://doi.org/10.1016/S0360-3016(00)01458-9

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. / Prados, Michael D; Wara, William M; Sneed, Penny K et al.
In: International Journal of Radiation Oncology Biology Physics, Vol. 49, 01.01.2001.

Research output: Contribution to journal › Article › peer-review

Prados, MD, Wara, WM, Sneed, PK, McDermott, M, Chang, SM, Rabbitt, J, Page, M, Malec, M, Davis, RL, Gutin, PH, Lamborn, K, Wilson, CB, Phillips, TL & Larson, DA 2001, 'Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.', International Journal of Radiation Oncology Biology Physics, vol. 49. https://doi.org/10.1016/S0360-3016(00)01458-9

Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics. 2001 Jan 1;49. doi: 10.1016/S0360-3016(00)01458-9

@article{d54ae49f46c545089fbedcf2a24d2046,

title = "Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.",

author = "Prados, \{Michael D\} and Wara, \{William M\} and Sneed, \{Penny K\} and Michael McDermott and Chang, \{Susan M\} and Jane Rabbitt and Margaretta Page and Mary Malec and Davis, \{Richard L\} and Gutin, \{Philip H\} and Kathleen Lamborn and Wilson, \{Charles B\} and Phillips, \{Theodore L\} and Larson, \{David A\}",

note = "In this prospective Phase III study, no survival or PFS benefit was seen with accelerated hyperfractionated irradiation to 70.4 Gy, nor was any benefit seen with DFMO as a radiosensitizer. Standard fractionated irradiation to 59.4 Gy remains the treatment of choice for newly diagnosed patients with ...",

year = "2001",

month = jan,

day = "1",

doi = "10.1016/S0360-3016(00)01458-9",

language = "American English",

volume = "49",

journal = "International Journal of Radiation Oncology Biology Physics",

}

TY - JOUR

T1 - Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

AU - Prados, Michael D

AU - Wara, William M

AU - Sneed, Penny K

AU - McDermott, Michael

AU - Chang, Susan M

AU - Rabbitt, Jane

AU - Page, Margaretta

AU - Malec, Mary

AU - Davis, Richard L

AU - Gutin, Philip H

AU - Lamborn, Kathleen

AU - Wilson, Charles B

AU - Phillips, Theodore L

AU - Larson, David A

N1 - In this prospective Phase III study, no survival or PFS benefit was seen with accelerated hyperfractionated irradiation to 70.4 Gy, nor was any benefit seen with DFMO as a radiosensitizer. Standard fractionated irradiation to 59.4 Gy remains the treatment of choice for newly diagnosed patients with ...

PY - 2001/1/1

Y1 - 2001/1/1

UR - https://www.ncbi.nlm.nih.gov/pubmed/11163499

U2 - 10.1016/S0360-3016(00)01458-9

DO - 10.1016/S0360-3016(00)01458-9

M3 - Article

VL - 49

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

ER -

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

Disciplines

Access to Document

Other files and links

Cite this